Utilization of Luteinizing Hormone-releasing Hormone Agonist in Pulmonary Leiomyomatosis
Overview
Authors
Affiliations
A patient presenting a recurrent episode of pulmonary leiomyomatosis has been treated with the LH-RH agonist buserelin at a dosage of 200 micrograms tid SC for 7 days, then 500 micrograms SC daily for a total period of 6 months. Basal serum E2 was suppressed during treatment and varied between 62 and 180 pmol/ml (mean, 129.4 +/- 14.5). Pulmonary symptoms completely disappeared during treatment, but no objective regression of the pulmonary lesions was observed. Because of the uncertainty of response of benign metastasizing leiomyomas to castration and because of the reversibility of the medical treatment, LH-RH agonist may be preferred to surgical castration in this pathology.
Multiple cavitating pulmonary nodules: rare manifestation of benign metastatic leiomyoma.
Lee S, Choi Y, Lee S, Shim S, Lee J, Kim Y J Thorac Dis. 2017; 9(1):E1-E5.
PMID: 28203428 PMC: 5303114. DOI: 10.21037/jtd.2016.11.112.
Lewis E, Chason R, DeCherney A, Armstrong A, Elkas J, Venkatesan A Fertil Steril. 2013; 99(7):2017-24.
PMID: 23465706 PMC: 3672263. DOI: 10.1016/j.fertnstert.2013.01.147.
Tori M, Akamatsu H, Mizutani S, Yoshidome K, Oyama T, Ueshima S Surg Today. 2008; 38(5):432-5.
PMID: 18560966 DOI: 10.1007/s00595-007-3609-2.
[Multiple lungs tumors found 17 years after hysterectomy--a case of benign metastasizing leiomyoma].
Mikami I, Yamamoto M, Nishimura H, Koizumi K, Gomibuchi M, Tanaka S Jpn J Thorac Cardiovasc Surg. 1998; 46(7):634-8.
PMID: 9750447 DOI: 10.1007/BF03217793.
Pulmonary benign metastasising leiomyoma: response to treatment with goserelin.
Jacobson T, Rainey E, Turton C Thorax. 1995; 50(11):1225-6.
PMID: 8553286 PMC: 475102. DOI: 10.1136/thx.50.11.1225.